Berger Amnon A, Sherburne Robert, Urits Ivan, Patel Haresh, Eskander Jonathan
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Cureus. 2020 Sep 2;12(9):e10211. doi: 10.7759/cureus.10211.
COVID-19 is a fatal, universal pandemic caused by the SARS-CoV-2 virus that has directly caused at least 95,235 deaths in the US by May 2020. It has a poor prognosis with a mortality rate as high as 21% in the general population at the height of the pandemic, a rate that is much higher in elderly patients, as well as those requiring intensive care unit (ICU) care. The role of inflammation in symptomatic COVID-19 is being studied, and it is hypothesized that hyper-inflammation is a causative factor in severe COVID-19 disease. Treatment options are limited and mostly rely on supportive care. Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy. Though it has been shown to act as an anti-inflammatory, it is not currently indicated for that purpose. Here, we describe, for the first time, the successful treatment of a COVID-19 patient with IPE.
2019冠状病毒病（COVID-19）是一种由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的致命性全球大流行疾病，截至2020年5月，在美国已直接导致至少95235人死亡。其预后较差，在疫情高峰期，普通人群的死亡率高达21%，老年患者以及需要重症监护病房（ICU）护理的患者死亡率更高。炎症在有症状的COVID-19中的作用正在研究中，据推测，过度炎症是重症COVID-19疾病的一个致病因素。治疗选择有限，主要依靠支持性治疗。二十碳五烯酸乙酯（IPE）是一种ω-3脂肪酸衍生物，已被证明可显著降低心血管疾病死亡率，并用作他汀类药物治疗的辅助药物。虽然它已被证明具有抗炎作用，但目前尚未用于此目的。在此，我们首次描述了使用IPE成功治疗一名COVID-19患者的情况。
